August 6, 2025Breast Cancer Research and TreatmentOpen Access

Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials

View Full Paper

Ask AI

Bookmark

Authors

PVPinyadapat VacharanukrauhFederation University KMKyle J. MillerAustralian Regenerative Medicine Institute SASheikh Mohammad AlifKhulna University

Discussion

Member takes

Implication

Systematic review reveals cardioprotective strategies to improve left ventricular ejection fraction in breast cancer patients undergoing anthracycline therapy, suggesting effective pharmacological options.

Key Points

Mineralocorticoid receptor antagonists showed the strongest cardioprotective effect in preventing cardiotoxicity.
The analysis covered 31 randomized controlled trials involving over 3,200 breast cancer patients and their outcomes.
Trimetazidine and dexrazoxane also demonstrated significant benefits, while β-blockers showed potential but more uncertainty.
A lack of direct head-to-head trials highlights the need for further studies to compare the effectiveness of these cardioprotective agents.

Cite This Study

Vacharanukrauh et al. (2025) studied this question.

synapsesocial.com/papers/689a0f99e6551bb0af8d152d https://doi.org/10.1007/s10549-025-07791-7

View Full Paper

Ask AI

Bookmark

Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider